AU2006244195B2 - Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV - Google Patents

Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV Download PDF

Info

Publication number
AU2006244195B2
AU2006244195B2 AU2006244195A AU2006244195A AU2006244195B2 AU 2006244195 B2 AU2006244195 B2 AU 2006244195B2 AU 2006244195 A AU2006244195 A AU 2006244195A AU 2006244195 A AU2006244195 A AU 2006244195A AU 2006244195 B2 AU2006244195 B2 AU 2006244195B2
Authority
AU
Australia
Prior art keywords
phenyl
cyclopropyl
benzyl
chcn
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006244195A
Other languages
English (en)
Other versions
AU2006244195A1 (en
Inventor
Jean Luc Girardet
Zhi Hong
Hong Woo Kim
Yung-Hyo Koh
Stephanie Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Publication of AU2006244195A1 publication Critical patent/AU2006244195A1/en
Application granted granted Critical
Publication of AU2006244195B2 publication Critical patent/AU2006244195B2/en
Priority to AU2012203082A priority Critical patent/AU2012203082A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2006244195A 2005-05-05 2006-05-05 Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV Ceased AU2006244195B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012203082A AU2012203082A1 (en) 2005-05-05 2012-05-25 Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67866705P 2005-05-05 2005-05-05
US60/678,667 2005-05-05
PCT/US2006/017677 WO2006122003A2 (en) 2005-05-05 2006-05-05 Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012203082A Division AU2012203082A1 (en) 2005-05-05 2012-05-25 Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV

Publications (2)

Publication Number Publication Date
AU2006244195A1 AU2006244195A1 (en) 2006-11-16
AU2006244195B2 true AU2006244195B2 (en) 2012-03-15

Family

ID=37397195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006244195A Ceased AU2006244195B2 (en) 2005-05-05 2006-05-05 Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV

Country Status (12)

Country Link
US (2) US8227601B2 (enExample)
EP (1) EP1877411B9 (enExample)
JP (2) JP5138585B2 (enExample)
CN (1) CN101233135B (enExample)
AT (1) ATE541848T1 (enExample)
AU (1) AU2006244195B2 (enExample)
BR (1) BRPI0611455A2 (enExample)
CA (1) CA2607021C (enExample)
ES (1) ES2380951T3 (enExample)
MX (1) MX2007013715A (enExample)
WO (1) WO2006122003A2 (enExample)
ZA (1) ZA200709481B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06002069A (es) * 2003-09-25 2006-05-19 Janssen Pharmaceutica Nv Derivados de purina que inhiben la replicacion del vih.
WO2006122003A2 (en) 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
KR20090103897A (ko) * 2006-12-28 2009-10-01 다이쇼 세이야꾸 가부시끼가이샤 피라졸로피리미딘 화합물
ES2389752T3 (es) 2007-12-14 2012-10-31 Ardea Biosciences, Inc. Inhibidores de la transcriptasa inversa
KR20130066703A (ko) 2008-02-06 2013-06-20 노파르티스 아게 피롤로［２,３­ｄ］피리미딘 및 티로신 키나제 억제제로서 그의 용도
WO2010111406A2 (en) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
HRP20171720T1 (hr) * 2013-06-27 2017-12-29 Janssen Sciences Ireland Uc Derivati pirolo [3,2-d] pirimidina za liječenje virusnih infekcija i drugih bolesti
JP6190076B2 (ja) 2014-04-25 2017-08-30 ファイザー・インク 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用
CN113563342A (zh) 2015-02-13 2021-10-29 达纳－法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
CN106188060A (zh) * 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
KR102048719B1 (ko) * 2015-08-13 2019-11-26 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
CN106117242B (zh) * 2016-06-27 2018-08-03 山东大学 四氢噻喃并嘧啶类衍生物及其制备方法与应用
CN107793417B (zh) * 2016-09-05 2020-06-09 复旦大学 吡咯并[2,3-d]嘧啶类化合物及其盐，及制备方法和药用用途
CN106749266B (zh) * 2016-11-14 2019-01-22 山东大学 吡咯并[2,3-d]嘧啶类化合物的高效制备方法
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN111499639B (zh) * 2019-01-31 2022-03-04 四川大学华西医院 嘧啶酮衍生物及其在制药中的应用
US20230279006A1 (en) * 2020-07-08 2023-09-07 Klotho Therapeutics, Inc. Novel compounds and methods for increasing klotho gene expression
CA3202990A1 (en) * 2020-11-27 2022-06-02 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Aminoheteroaryl kinase inhibitors
AU2024266528A1 (en) * 2023-05-04 2025-10-16 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic amine derivatives and pharmaceutical composition comprising same
WO2025184609A1 (en) * 2024-03-01 2025-09-04 Gilead Sciences, Inc. Antiviral compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028479A2 (en) * 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
JP2002529469A (ja) 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれに関する方法
WO2000037471A1 (en) * 1998-12-23 2000-06-29 Neurogen Corporation 2-amino-9-alkylpurines: gaba brain receptor ligands
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
YU25500A (sh) * 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AP2065A (en) 2003-02-07 2009-11-26 Janssen Pharmaceutica Nv Pyrimidine derivatives for the prevention of HIV infection
EP1807430B1 (en) 2004-10-29 2014-07-23 Janssen R&D Ireland Hiv inhibiting bicyclic pyrimidine derivatives
WO2006122003A2 (en) 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028479A2 (en) * 2003-09-25 2005-03-31 Janssen Pharmaceutica N.V. Hiv replication inhibiting purine derivatives

Also Published As

Publication number Publication date
WO2006122003A3 (en) 2007-01-04
JP2008540454A (ja) 2008-11-20
ES2380951T9 (es) 2012-12-21
CN101233135A (zh) 2008-07-30
ATE541848T1 (de) 2012-02-15
CA2607021A1 (en) 2006-11-16
WO2006122003A2 (en) 2006-11-16
CA2607021C (en) 2013-10-29
ES2380951T3 (es) 2012-05-21
AU2006244195A1 (en) 2006-11-16
US20120226037A1 (en) 2012-09-06
US20090124802A1 (en) 2009-05-14
JP2012188454A (ja) 2012-10-04
ZA200709481B (en) 2008-11-26
EP1877411A4 (en) 2008-10-22
EP1877411B9 (en) 2012-08-29
MX2007013715A (es) 2008-01-28
US8354532B2 (en) 2013-01-15
EP1877411A2 (en) 2008-01-16
EP1877411B1 (en) 2012-01-18
CN101233135B (zh) 2012-10-03
BRPI0611455A2 (pt) 2010-09-08
US8227601B2 (en) 2012-07-24
JP5138585B2 (ja) 2013-02-06

Similar Documents

Publication Publication Date Title
AU2006244195B2 (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
Rusinov et al. Azolo [5, 1-c]-1, 2, 4-triazines as a new class of antiviral compounds
RU2103272C1 (ru) Бициклические гетероциклические амины и их фармацевтически приемлемые соли, бициклические гетероциклические амины и их фармацевтически приемлемые соли в качестве ингибитора реакционноспособного кислорода
Li et al. Synthesis and Anti‐tumor Activities of Novel Pyrazolo [1, 5‐a] pyrimidines
Zhang et al. Highly facile and regio-selective synthesis of pyrazolo [1, 5-a] pyrimidines via reactions of 1, 2-allenic ketones with aminopyrazoles
US6387912B1 (en) Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia
CA1320203C (en) Intermediates for 9-deazaguanines
Ghozlan et al. Studies with functionally substituted enamines: Synthesis of new aminoazolo-pyrimidines and-1, 2, 4-triazines
Stanovnik et al. Reactions of N‐heteroarylformamide oximes and N‐heteroarylacetamide oximes with N, N‐dimethylformamide dimethyl acetal. Synthesis of 2‐methyl‐s‐triazolo [1, 5‐x] azines and N‐methylcyanoaminoazines
Al-Afaleq Heterocyclic synthesis via enaminonitriles: an efficient, one step synthesis of some novel azolo [1, 5-α] pyrimidine, pyrimido [1, 2-α]-benzimidazole, pyrido [1, 2-α] benzimidazole pyrimidine and pyrazole derivatives
Mohamed et al. Synthesis and antimicrobial evaluation of some 6-aryl-5-cyano-2-thiouracil derivatives
Gut Aza analogs of pyrimidine and purine bases of nucleic acids
El‐Taweel et al. Cyclization reactions of 5‐aminopyrazoles with β‐ketoesters, enamines and β‐keto anilides: new synthetic routes to pyrazolo [1, 5‐a] Pyrimidine derivatives
Khan et al. Condensed heterocycles: synthesis and antifungal activity of. pi.-deficient pyrimidines linked with. pi.-rich heterocycles
Carvalho et al. Efficient conversion of 6-cyanopurines into 6-alkoxyformimidoylpurines
AU2012203082A1 (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
El-Badawi et al. Synthesis and Biological Evaluation of Some Novel N, N′-Bis-(1, 2, 4-Triazin-4-Yl) Dicarboxylic Acid Amides and Some Fused Rings with 1, 2, 4-Triazine Ring
Babkov et al. Methods for the synthesis of aza (deaza) xanthines as a basis of biologically active compounds
EP2905024A1 (en) Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae
Al-Azmi Novel 6-substituted pyrimidines and pyrimido [5, 4-d] pyrimidines from (2-acetamido-1, 2-dicyanovinyl) ammonium chloride
ITOH et al. Syntheses of some tricyclic heterocycles from 5, 6-diamino-1, 3-dimethyluracil
Al-Azmi et al. Reactions of 9-aryl-6-cyanopurines with primary amines
Hamed Cyclization Reactions of Chloro-Substituted 2-Azoniaallene Salts with Bifunctional Nucleophiles
Sanemitsu et al. 1, 2, 4‐triazines. 7. Regioselective n2‐amination of 3‐methylthio‐1, 2, 4‐triazin‐5 (2H)‐ones. A novel synthesis of [1, 2, 4] triazolo [2, 3‐b][1, 2, 4] triazinones and‐triazine
ONTO 18 Science Drive 4, Singapore 117543, Singapore. E-mail: phacwk@ nus. edu. sg

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD THE NAME OF CO-INVENTOR HONG, ZHI

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ GIRARDET, JEAN LUC; SHAW, STEPHANIE; KOH, YUNG-HYO; KIM, HONG WOO; HONG, ZHI .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ KIM, HONG WOO; KOH, YUNG-HYO; SHAW, STEPHANIE; GIRARDET, JEAN LUC AND HONG, ZHI

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired